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Salvage chemotherapy for relapsed/refractory FLT3-ITD-mutant
acute myeloid leukemia (AML) is associated with a low complete
remission (CR) rate (20–26%), despite the sequential use of a
FLT3 inhibitor.1 FLT3 ligand rises precipitously after chemotherapy
administration in advanced AML and is thought to have a
detrimental effect on the activity of FLT3 inhibitors.1 Most studies
involving FLT3 inhibitors deliver the tyrosine kinase inhibitor (TKI)
concomitantly with, or sequentially after, chemotherapy. This
followed prior assertions that FLT3 inhibitors could induce cell
cycle arrest, thus antagonising the effects of cell cycle-dependent
chemotherapy.2 The clinical effects of FLT3 inhibitor priming in
patients with FLT3-ITD AML receiving chemotherapy has not been
previously reported. Pre-clinical studies by Taylor et al.3 proposed
that FLT3 inhibitor priming could induce leukemic progenitors
into S-phase, thereby sensitising FLT3-ITD-mutant AML to
subsequent chemotherapy. Administration of FLT3 inhibitors
before chemotherapy may avoid the neutralising effects of rising
FLT3 ligand levels after chemotherapy.1 Furthermore, a non-
cytotoxic pre-phase may attenuate the risks associated with
tumour lysis syndrome in patients with severe baseline hyper-
leukocytosis. We therefore report the outcome of 10 patients with
relapsed or refractory FLT3-ITD AML treated with the multikinase
(including FLT3) inhibitor sorafenib (400 mg b.i.d.) for 7 days as
pre-phase, followed by salvage chemotherapy with FLAG–Amsa
(fludarabine 30mg/m2 days 1–5, cytarabine 2 g/m2 days 1–5,
G-CSF 300 μg subcutaneously days 0–6 and amsacrine 100mg/m2
days 1–3). Patients received sorafenib from their treating
physicians in an off-label manner. The schedule allowed the
effects of sorafenib priming to be assessed without the
confounding effects of further TKI prior to response evaluation.
Restriction of sorafenib to 7 days during salvage was also a
pragmatic one to minimise costs related to hospital-funded drug
provision. Sorafenib is known to be metabolised by CYP3A4 to
sorafenib N-oxide, which has active potency against FLT3-ITD.4
Azoles were therefore avoided during the sorafenib pre-phase.
Among the 10 patients treated, CR or CR with incomplete blood
count recovery (CRi) was achieved in 50% (Table 1). Sorafenib was
highly effective in rapidly suppressing hyperleukocytosis in two
patients (#6 and #9) with baseline peripheral blood white cell
counts falling from 176 and 184 × 109/l on day 1, to 0.9 and
2.1 × 109/l on day 7, respectively (Table 1). Three patients who
achieved CR/CRi remain alive after 19+ (#1), 14+ (#2) and 2 (#5)
months. In two patients, serum FLT3 ligand levels were obtained.
Table 1. Patient characteristics, response and outcome
Pt Age CG Prior therapy Sorafenib day and
WCC x 109/l
Marrow response day 28 post
sorafenib–FLAG–Amsa
Subsequent therapy OS
(months)
1 62 N 7+3 D1= n/a
D7= 3.0
CRi AlloSCT 19+
2 40 N HiDAC-3, AlloHSCT D1= n/a
D7= 2.6
CRi DLI, sorafenib 14+
3 17 N 7+3 D1= 0.9
D7= 0.9
CRi DUCBT 5
4 44 N 7+3 D1= 0.3
D7= 0.2
CRi Nil 4
5 55 +4 7+3, HiDAC-1 D1= 1.3
D7= 6.4
CR Sorafenib–FLAG–Amsa 2+
6 46 +8 HiDAC-3 D1= 184
D7= 2.1
Resistant AlloSCT, sorafenib 8
7 24 +8 HiDAC-3, AlloHSCT D1= 0.6
D7= 0.5
Resistant DLI, melphalan, clinical trials 7
8 25 N 7+3 D1= 176
D7= 0.9
Resistant Hydroxyurea Thioguinine, sorafenib 6
9 34 +8 7+3 D1= 27.6
D7= 4.9
Resistant Nil 5
10 64 N ICE, 5+2 D1= 22
D7= 2.8
Resistant Nil 2
Abbreviations: alloSCT, allogeneic stem cell transplant; CG, cytogenetics; CR, complete remission; CRi, complete remission with incomplete blood count
recovery; DLI, donor lymphocyte infusion; DUCBT, double unrelated cord blood transplant; FLAG–Amsa, see Fong et al.5; HiDAC-3, cytarabine 3 g/m2 bd. days
1, 3, 5, 7+idarubicin 12 mg/m2 days 1–2; ICE, idarubicin 9mg/m2 days 1–3+cytarabine 3 g/m2 bd days 1,3,5,7+etoposide 75mg/m2 days 1–7; 5+2, cytarabine
100mg/m2 days 1–5+idarubicin 12mg/m2 days 1–2; N, normal; n/a, result not available; Pt, patient; WCC, white cell count; 7+3, cytarabine 100 mg/m2 days 1–7
+idarubicin 12mg/m2 days 1–3.
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Plasma FLT3 ligand levels did not rise above 70 pg/ml in either
patient during the first week of sorafenib (not shown). These results
suggest that FLT3 inhibitors given as pre-phase before chemotherapy
does not impede the clinical response to salvage therapy in
patients with relapsed/refractory FLT3-ITD-mutant AML while
delivering rapid cytoreductions in those affected by severe
hyperleukocytosis before chemotherapy. Response durations were
short in three of the five patients, suggesting the need for
additional post-remission strategies. Salvage therapy with
sorafenib–FLAG–Amsa, involving only 7 days of sorafenib exposure
before chemotherapy, was an economically prudent, well-tolerated
and efficacious regimen in relapsed/refractory FLT3-ITD AML.
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